Trial document
DRKS00007109
Trial Description
Title
Noninterventional study on the administration of Spasmex® 45 mg coated tablets in elderly female and male patients suffering from symptoms of urge in daily urological practice - a noninterventional study with epidemiological aspects
Trial Acronym
NIS-056
URL of the Trial
[---]*
Brief Summary in Lay Language
In the course of this study the routine use of the registered drug Spasmex 45 mg coated tablets for the indication of overactive bladder will be documented for scientific purposes. Elderly (≥ 65 years of age) male and female patients will be enrolled in the study, who visit a urological practice due to symptoms of overactive bladder, and who receive prescription for Spasmex 45 mg coated tablets following routine diagnosis by the treating physician.
The aims of the study is to determine:
- the extent of anticholinergic drug burden with potential cognitive impairment
- the extent of morbidity
- efficacy and tolerability of the drug used
- divisibility of the coated tablet into three parts.
Brief Summary in Scientific Language
Symptoms of an overactive bladder (OAB) (urgency, frequency and/or urge incontinence) are highly prevalent, with an increasing frequency in old age (Milsom et al. 2001). OAB affects the quality of life through to social isolation and depression (Griebling 2013). Multi-medication and additionally metabolites with anticholinergic effects may cause adverse reactions such as delirium, falls, cognitive impairment (Ancelin et al. 2006, Fox et al. 2011), and as a result lead to loss of independence (Pasina et al. 2013, Lertxundi et al. 2013), and to further deterioration of the patient's health status. Treatment with quarternary anticholinergic drugs, which are largely free of central nervous system effects, might be an approach for effective treatment of OAB without increasing the anticholinergic burden of the patients.
The described study with patients suffering from urge-symptoms will be divided into three parts:
a) an epidemiological survey
i. to determine the anticholinergic burden caused by drugs using the ACBS score and
ii. to determine and quantify the morbidity using the CIRS-G score.
b) a prospective investigation of efficacy and tolerabilty of Spasmex® 45mg coated tablets
c) a survey on the divisibility of Spasmex® 45mg coated tablets.
Do you plan to share individual participant data with other researchers?
[---]*
Description IPD sharing plan:
[---]*
Organizational Data
- DRKS00007109
- 2014/10/29
- [---]*
- no
- Approved
- 2014-343-f-S, Ethik-Kommission der Ärztekammer Westfalen-Lippe und der med. Fakultät der Westfälischen Wilhelms-Universität Münster
Secondary IDs
- [---]*
Health Condition or Problem studied
- LLT,10059617:overactive bladder
- N32.8 - Other specified disorders of bladder
Interventions/Observational Groups
-
There is only one treatment arm. There are 3 visits per patient. The period of time between the visits corresponds to the general practice. A period of time of at least 10 days between the visits is recommended.
It will be recorded:
1. Demographic data on visit 1
2. Symptoms of overactiv bladder on visit 1, 2, and 3
3. Morbidity using the CIRS-G questionnaire on visit 1
4. Medicinal pre-treatment on visit 1
5. Comedication with anticholinergic burden using the ACBS scale on visit 1, 2 and 3
6. Additional relevant comedication on visit 1, 2 and 3
7. Documentation of the therapy regimen
8. Questioning of physician and patient regarding efficacy and tolerability on visit 2 and 3
9. Questioning of patient regarding the divisibility of the coated tablet on visit 3
10. Questioning of patient regarding adverse events on visit 2 and 3.
11. Documentation of further treatment
Characteristics
- Non-interventional
- Observational study
- Single arm study
- Open (masking not used)
- [---]*
- Uncontrolled/Single arm
- Other
- Single (group)
- N/A
- N/A
Primary Outcome
a) to determine the anticholinergic burden caused by drugs using the total score of Anticholinergic Cognitive Burden Scale (ACBS) on visit 1, 2 and 3
b) to determine and quantify the morbidity using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) on visit 1
c) to detemine the efficacy using the following parameters:
- number of micturitions per day (on visit 1, 2 and 3)
- intensity of urgency (on visit 1, 2 and 3)
- incontinence episodes (on visit 1, 2 and 3)
- overall assessment of efficacy by patient and by physician (on visit 2 and 3)
d) to determine the divisibility of the coated tablets using an ordinal scale (on visit 3)
e) overall assessment of tolerability by patient and by physician (on visit 2 and 3)
f) documentation of side effects (on visit 2 and 3)
A period of time of at least 10 days between the visits is recommended.
Secondary Outcome
See Primary outcome. In this noninterventional study there are no primary or secondary endpoints. All variables will be evaluated descriptively. No hypothesis will be tested, no comparison of different populations will be done.
Countries of Recruitment
- Germany
Locations of Recruitment
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
- Doctor's Practice
Recruitment
- Actual
- 2014/11/03
- 1250
- Multicenter trial
- National
Inclusion Criteria
- Both, male and female
- 65 Years
- no maximum age
Additional Inclusion Criteria
at least 65 years of age; symptoms of overactive bladder; prescription of Spasmex 45mg coated tablets
Exclusion Criteria
younger than 65 years of age
Addresses
-
start of 1:1-Block address primary-sponsor
- Dr. R. Pfleger GmbH
- 96045 Bamberg
- Germany
end of 1:1-Block address primary-sponsorstart of 1:1-Block address contact primary-sponsor- 0951/6043-0
- 0951/6043-29
- [---]*
- http://www.dr-pfleger.de
end of 1:1-Block address contact primary-sponsor -
start of 1:1-Block address other
- Ev. Krankenhaus Witter gGmbHUrologische Klinik
- Mr. Priv.-Doz. Dr. med. Andreas Wiedemann
- Pferdebachstr. 27
- 58455 Witten
- Germany
end of 1:1-Block address otherstart of 1:1-Block address contact other- 02302/175-2521
- [---]*
- awiedemann at diakonie-ruhr.de
- http://www.evk-witten.de/ev_krankenhaus_witten/medizin/klinik_fuer_urologie
end of 1:1-Block address contact other -
start of 1:1-Block address scientific-contact
- Dr. R. Pfleger GmbH
- Ms. Dr. rer. nat. Claudia Neumeister
- Emil Kemmer Str. 33
- 96103 Hallstadt
- Germany
end of 1:1-Block address scientific-contactstart of 1:1-Block address contact scientific-contact- 0951/6043-0
- 0951/6043-29
- claudia.neumeister at dr-pfleger.de
- http://www.dr-pfleger.de
end of 1:1-Block address contact scientific-contact -
start of 1:1-Block address public-contact
- Dr. R. Pfleger GmbH
- Ms. Dr. rer. nat. Claudia Neumeister
- Emil Kemmer Str. 33
- 96103 Hallstadt
- Germany
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- 0951/6043-0
- 0951/6043-29
- nis-056 at dr-pfleger.de
- http://www.dr-pfleger.de
end of 1:1-Block address contact public-contact
Sources of Monetary or Material Support
-
start of 1:1-Block address materialSupport
- Dr. R. Pfleger GmbH
- 96045 Bamberg
- Germany
end of 1:1-Block address materialSupportstart of 1:1-Block address contact materialSupport- 0951/6043-0
- 0951/6043-29
- [---]*
- http://www.dr-pfleger.de
end of 1:1-Block address contact materialSupport
Status
- Recruiting complete, follow-up complete
- 2015/10/30
Trial Publications, Results and other Documents
* This entry means the parameter is not applicable or has not been set.